Grupo para la caracterización molecular de las neoplasias hematológicas
![Foto de Grupo para la caracterización molecular de las neoplasias hematológicas](/img/grupo.png)
![Foto de Mayo Clinic](/img/noimage_org.png)
Mayo Clinic
Rochester, Estados UnidosPublicaciones en colaboración con investigadores/as de Mayo Clinic (28)
2024
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
2023
-
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk
International Journal of Cancer, Vol. 152, Núm. 2, pp. 239-248
-
Identification of novel genetic loci for risk of multiple myeloma by functional annotation
Leukemia
-
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
International Journal of Molecular Sciences, Vol. 24, Núm. 10
2022
-
Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 31, Núm. 9, pp. 1863-1866
-
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
Blood Advances, Vol. 6, Núm. 22, pp. 5835-5843
2020
2019
-
Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report
Journal of Oncology Pharmacy Practice, Vol. 25, Núm. 4, pp. 998-1002
-
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312
-
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469
-
Spectrum and functional validation of PSMB5 mutations in multiple myeloma
Leukemia, Vol. 33, Núm. 2, pp. 447-456
2018
-
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
Blood Cancer Journal, Vol. 8, Núm. 12
2017
-
Second primary malignancies in multiple myeloma: An overview and IMWG consensus
Annals of Oncology, Vol. 28, Núm. 2, pp. 228-245
2016
-
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low‐dose dexamethasone versus high‐dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Haematologica, Vol. 101, Núm. 7, pp. 872-878
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2015
-
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients
Nature Communications, Vol. 6
-
Revised international staging system for multiple myeloma: A report from international myeloma working group
Journal of Clinical Oncology, Vol. 33, Núm. 26, pp. 2863-2869
-
Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement
Journal of Clinical Oncology, Vol. 33, Núm. 6, pp. 657-664
2014
-
Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database
Nature Genetics, Vol. 46, Núm. 2, pp. 107-115